GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Debt-to-EBITDA

Helix BioPharma (TSX:HBP) Debt-to-EBITDA : 0.00 (As of Jul. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Helix BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$0.00 Mil. Helix BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$0.00 Mil. Helix BioPharma's annualized EBITDA for the quarter that ended in Jul. 2024 was C$-21.10 Mil. Helix BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Helix BioPharma's Debt-to-EBITDA or its related term are showing as below:

TSX:HBP's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.41
* Ranked among companies with meaningful Debt-to-EBITDA only.

Helix BioPharma Debt-to-EBITDA Historical Data

The historical data trend for Helix BioPharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Debt-to-EBITDA Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.39 -0.38 - -

Helix BioPharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Helix BioPharma's Debt-to-EBITDA

For the Biotechnology subindustry, Helix BioPharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Debt-to-EBITDA falls into.



Helix BioPharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Helix BioPharma's Debt-to-EBITDA for the fiscal year that ended in Jul. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -9.243
=0.00

Helix BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -21.096
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jul. 2024) EBITDA data.


Helix BioPharma  (TSX:HBP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Helix BioPharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.